
ICON Public Limited Company ICLR
$ 176.57
-3.31%
Annual report 2024
added 01-10-2026
ICON Public Limited Company Accounts Receivables 2011-2026 | ICLR
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables ICON Public Limited Company
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 1.34 B | 715 M | 528 M | 415 M | 380 M | 416 M | 409 M | 371 M | 343 M | 285 M | 201 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.34 B | 201 M | 491 M |
Quarterly Accounts Receivables ICON Public Limited Company
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 1.37 B | 1.34 B | 1.34 B | 677 M | 660 M | 715 M | 511 M | 473 M | 526 M | 528 M | 408 M | 432 M | 415 M | 415 M | 373 M | 405 M | 394 M | 380 M | 345 M | 360 M | 341 M | 416 M | 404 M | 367 M | 362 M | 409 M | 387 M | 358 M | 362 M | 371 M | 373 M | 383 M | 338 M | 343 M | 360 M | 306 M | 261 M | 285 M | 231 M | 228 M | 195 M | 201 M | 197 M | 171 M | 188 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.37 B | 171 M | 442 M |
Accounts Receivables of other stocks in the Diagnostics research industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
114 M | - | -17.87 % | $ 25.9 M | ||
|
Anixa Biosciences
ANIX
|
173 K | $ 3.11 | -2.51 % | $ 101 K | ||
|
Accelerate Diagnostics
AXDX
|
2.42 M | - | -61.36 % | $ 2.46 M | ||
|
BioNano Genomics
BNGO
|
4.75 M | $ 1.45 | -3.67 % | $ 1.84 M | ||
|
Aspira Women's Health
AWH
|
1.24 M | - | -6.19 % | $ 10.5 M | ||
|
Burning Rock Biotech Limited
BNR
|
88.2 M | $ 30.5 | -4.72 % | $ 328 M | ||
|
Biocept
BIOC
|
2.15 M | - | -13.05 % | $ 7.29 M | ||
|
Castle Biosciences
CSTL
|
51.2 M | $ 40.78 | 1.92 % | $ 1.13 B | ||
|
Co-Diagnostics
CODX
|
304 K | - | - | $ 79.8 M | ||
|
DexCom
DXCM
|
974 M | $ 70.44 | 1.29 % | $ 27.2 B | ||
|
Chembio Diagnostics
CEMI
|
6.54 M | - | 0.22 % | $ 16.8 M | ||
|
Guardant Health
GH
|
110 M | $ 113.62 | 1.32 % | $ 13.9 B | ||
|
Global Cord Blood Corporation
CO
|
416 M | - | - | $ 399 M | ||
|
DermTech
DMTK
|
2.58 M | - | -11.32 % | $ 2.94 M | ||
|
Illumina
ILMN
|
735 M | $ 147.36 | 4.03 % | $ 23.4 B | ||
|
CareDx, Inc
CDNA
|
51.1 M | $ 20.08 | 0.35 % | $ 1.08 B | ||
|
Danaher Corporation
DHR
|
3.54 B | $ 234.95 | -0.44 % | $ 172 B | ||
|
DarioHealth Corp.
DRIO
|
3.16 M | $ 12.48 | 0.28 % | $ 354 M | ||
|
Enzo Biochem
ENZ
|
3.99 M | - | -8.98 % | $ 14.8 K | ||
|
Fulgent Genetics
FLGT
|
69 M | $ 27.65 | -1.53 % | $ 836 M | ||
|
HTG Molecular Diagnostics
HTGM
|
1.42 M | - | -20.0 % | $ 1.06 M | ||
|
Exact Sciences Corporation
EXAS
|
249 M | $ 102.21 | -0.22 % | $ 18.9 B | ||
|
Lantheus Holdings
LNTH
|
321 M | $ 66.02 | 2.75 % | $ 4.57 B | ||
|
Medpace Holdings
MEDP
|
296 M | $ 602.32 | -1.41 % | $ 18.6 B | ||
|
IQVIA Holdings
IQV
|
3.2 B | $ 234.18 | -1.47 % | $ 42.5 B | ||
|
QIAGEN N.V.
QGEN
|
381 M | - | - | $ 10.6 B | ||
|
Heska Corporation
HSKA
|
29.5 M | - | - | $ 1.31 B | ||
|
Neogen Corporation
NEOG
|
153 M | $ 9.28 | 0.27 % | $ 2.01 B | ||
|
National Research Corporation
NRC
|
12.4 M | $ 22.06 | -0.72 % | $ 541 M | ||
|
Charles River Laboratories International
CRL
|
721 M | $ 219.04 | -0.3 % | $ 11.3 B | ||
|
OPKO Health
OPK
|
118 M | $ 1.3 | 1.56 % | $ 902 M | ||
|
Pacific Biosciences of California
PACB
|
36.6 M | $ 2.36 | 6.79 % | $ 599 M | ||
|
Quest Diagnostics Incorporated
DGX
|
1.3 B | $ 188.87 | -0.33 % | $ 21 B | ||
|
Biodesix
BDSX
|
8.6 M | $ 8.85 | 12.25 % | $ 1.15 B | ||
|
Mettler-Toledo International
MTD
|
687 M | $ 1 409.56 | -3.5 % | $ 29.9 B | ||
|
Laboratory Corporation of America Holdings
LH
|
1.94 B | $ 272.02 | 0.42 % | $ 22.8 B | ||
|
IDEXX Laboratories
IDXX
|
474 M | $ 688.67 | -3.73 % | $ 56.8 B | ||
|
Myriad Genetics
MYGN
|
121 M | $ 5.65 | -4.56 % | $ 512 M | ||
|
ENDRA Life Sciences
NDRA
|
6.85 K | $ 4.67 | -2.3 % | $ 2.51 M | ||
|
Agilent Technologies
A
|
1.17 B | $ 135.52 | -2.95 % | $ 41.2 B |